The treatment paradigm for patients with metastatic cancer has shifted in the era of oligometastatic disease,1 novel systemic therapy, and local ablative therapy options such as stereotactic ablative body radiotherapy (SABR). The equation of “metastatic” with “incurable” has been challenged, as an increasing number of patients with stage IV disease have long-term survival outcomes. In the treatment of oligometastasis, several clinical trials have recently demonstrated the survival benefits of SABR.2-4 For patients with diffuse metastatic disease or those who are otherwise being treated with palliative intent, the optimal radiation technique has also been a subject of scrutiny.5 To this end, in 2016 the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center established a dedicated program for patients with metastatic cancer to address the specific needs of these patients, the Precision Radiation for Oligometastatic and Metastatic Disease, or PROMISE, Program.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tsai CJ, Gomez DR, Yang TJ. Metastatic Disease as a Distinct Discipline in Radiation Oncology. JAMA Oncol. 2021;7(1):21–22. doi:10.1001/jamaoncol.2020.1824
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: